A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education, and prevention. MD Anderson has ranked among the nation's top ...

“That’s quite an accomplishment,” says Allison, professor and chair of immunology at The University of Texas MD Anderson Cancer Center. Ipilimumab received FDA approval for use in late-stage ...

For more information, click here. From MD Anderson Cancer Center The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer ...

During a March Becker’s Hospital Review webinar sponsored by LeanTaaS, LeeAnn Mengel, RN, MBA, CMPE, FACHE, vice president and administrator of Baptist MD Anderson Cancer Center (Jacksonville ...

Enrollment is ongoing at multiple sites, including The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. The first patient has been enrolled in the phase 3 ...